Improved loss from operations by 31% Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections Forged commercial agreement for Phexxi in Middle East SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the third quarter and... Read More

Shelf utilization inclusive of the ELOC and ATM, will be suspended during the stale period beginning Monday, November 11, 2024 MOUNTAIN VIEW, Calif. / Nov 08, 2024 / Business Wire / Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today provided an update to its shareholders on the utilization of its Equity Line of Credit (“ELOC”)... Read More

MOUNTAIN VIEW, Calif. / Nov 07, 2024 / Business Wire / Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target acquisition, Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”). Shareholders of Appili overwhelmingly voted in favor of a plan of arrangement for Aditxt to acquire... Read More

SAN DIEGO , Nov. 6, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) ("Evofem" or the "Company") today announced it has secured voting agreements with certain of its Series E-1 stockholders and convertible noteholders to ensure they will vote in favor of the proposed merger with Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt") subsidiary Adifem, Inc., under the Amended and Restated Merger Agreement , as amended (the "A&R... Read More

MOUNTAIN VIEW, Calif. / Oct 31, 2024 / Business Wire / Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target acquisition, Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”), announcing that the U.S. Food and Drug Administration (“FDA”) has provided positive feedback regarding... Read More

MOUNTAIN VIEW, Calif. / Oct 30, 2024 / Business Wire / Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A session with CEO Amro Albanna this Friday, November 1, 2024, at 11:30 AM ET. This update aims to connect with our stakeholders, including investors and the public, offering insights... Read More

MOUNTAIN VIEW, Calif. / Oct 29, 2024 / Business Wire / Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to its Board of Directors. With over 20 years of experience advising public companies on corporate governance, mergers and acquisitions, and shareholder relations, Ms. Hermina... Read More

MOUNTAIN VIEW, Calif. / Oct 28, 2024 / Business Wire / Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced the achievement of a key milestone under the Amended and Restated Merger Agreement, as amended (the “A&R Merger Agreement”) toward completion of its intended acquisition of women’s health innovator Evofem... Read More

Event to Focus on the Status of the Acquisition, Plans Post-Acquisition for Evofem, and Q&A MOUNTAIN VIEW, Calif. / Oct 21, 2024 / Business Wire / Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced a virtual fireside chat set for October 28, 2024, at 11:30 AM Eastern Time. The event will be hosted by Amro Albanna,... Read More

Appili has a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets, and subject to the renewal of certain legislation, two programs potentially eligible for FDA Priority Review Vouchers MOUNTAIN VIEW, Calif. / Oct 10, 2024 / Business Wire / Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), an innovation platform dedicated to... Read More

MOUNTAIN VIEW, Calif. / Oct 09, 2024 / Business Wire / Aditxt, Inc. (“Aditxt” “Company”) (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A session with CEO Amro Albanna this Friday, October 11, 2024, at 11:30 AM EDT. This update aims to connect with our stakeholders, including investors and the public, offering insights into the... Read More

MOUNTAIN VIEW, Calif. & SAN DIEGO / Oct 08, 2024 / Business Wire / Aditxt, Inc. (“Aditxt” ) (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, and Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), a pioneer in women's health, today announced the completion of the Third Parent Equity Investment under the Amended and Restated Merger Agreement, as amended (the “Agreement”). This... Read More

Acquisition target Evofem reported revenue of $7.8 million for the six months ended June 30, 2024 Acquisition target Appili has received approximately $6.0 million of the total $14.0 million to date in a non-dilutive funding commitment from DoD Shelf registration statement and resale registration statement for Equity Line of Credit declared Effective by the SEC Effected a 1-for-40 reverse split of its common stock, which was... Read More

MOUNTAIN VIEW, Calif. / Sep 27, 2024 / Business Wire / Aditxt, Inc . (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, announced today that it will effect a 1-for-40 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on October 2, 2024, the Company’s common stock will trade on a post-split basis under... Read More

Companies Targeting Closing in Fourth Quarter of 2024 MOUNTAIN VIEW, Calif. / Sep 24, 2024 / Business Wire / Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, today announced that its acquisition target, Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), today filed a preliminary proxy to seek stockholder approval of transactions... Read More

Endometriosis Affects Approximately 190 Million Women Worldwide Non-invasive MET ™ Diagnostic Test for Endometriosis Leverages Novel Biomarker: A Specific Deletion in Mitochondrial DNA Pearsanta’s MET is Seeking to Become the First and Only Validated and Commercialized Blood-based Biomarker Test for Endometriosis MOUNTAIN VIEW, Calif. & SAN DIEGO / Sep 20, 2024 / Business Wire / Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the... Read More

MOUNTAIN VIEW, Calif. & SAN DIEGO / Sep 09, 2024 / Business Wire / Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating health innovations, and women’s health pioneer, Evofem Biosciences, Inc. (OTCQB: EVFM) (“Evofem”) today announced they have entered into the Second Amendment to the Amended and Restated Agreement and Plan of Merger (the “Second Amendment”), under which... Read More

Prostate Cancer Diagnostic Market: Expected Growth from $6.2 Billion in 2023 to $11.5 Billion by 2032 Amid Rising Demand for Early Detection Technologies MOUNTAIN VIEW, Calif. / Sep 04, 2024 / Business Wire / Aditxt, Inc . ("Aditxt") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announced that its subsidiary, Pearsanta, Inc. (“Pearsanta”), has submitted a grant... Read More

MOUNTAIN VIEW, Calif. / Aug 29, 2024 / Business Wire / Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it will present virtually and participate in one-on-one investor meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel in... Read More

MOUNTAIN VIEW, Calif. / Aug 26, 2024 / Business Wire / Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc. (“Pearsanta”), appointed Christoper Mitton as President. Christopher Mitton brings over 20 years of leadership experience in the medical diagnostics industry,... Read More

MOUNTAIN VIEW, Calif. / Aug 21, 2024 / Business Wire / Aditxt, Inc. (“Aditxt” or “the Company”) (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it had entered into a third amending agreement with Appili Therapeutics, Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”), a biopharmaceutical company focused on developing innovative treatments... Read More

Improved loss from operations by 81% Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections Forged ex-U.S. commercial agreement for Phexxi in Middle East SAN DIEGO , Aug. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the second quarter and... Read More

MOUNTAIN VIEW, Calif. / Aug 13, 2024 / Business Wire / Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising innovations, announced the successful passage of all proposals at its recent annual shareholders' meeting. At the recent annual meeting, Aditxt shareholders approved all nine proposals presented. These proposals equip Aditxt with... Read More

MOUNTAIN VIEW, Calif. / Aug 09, 2024 / Business Wire / Aditxt, Inc. , (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the closing of a previously announced registered direct offering price at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 1,130,189 shares of... Read More

MOUNTAIN VIEW, Calif. / Aug 09, 2024 / Business Wire / Aditxt, Inc. , (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of an aggregate of 1,130,189 shares of common stock... Read More

Ovarian Cancer Diagnostic Market Growth: Projected Increase from $1.5 Billion in 2023 to $2.7 Billion by 2032 1 Amidst Current Challenges of Insufficiently Sensitive Blood Tests for Early Detection MOUNTAIN VIEW, Calif. / Aug 07, 2024 / Business Wire / Aditxt, Inc. ("Aditxt") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announced that its subsidiary, Pearsanta,... Read More

Appili, with a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets. Subject to the renewal of certain legislation, two programs are potentially eligible for FDA Priority Review Vouchers MOUNTAIN VIEW, Calif. / Jul 25, 2024 / Business Wire / Aditxt, Inc. (“Aditxt”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying... Read More

Pharma 1 anticipates filing UAE regulatory submission for Phexxi as a hormone-free contraceptive in Q3 2024 UAE contraceptive drug market is projected to reach $185.1 million by 2030 SAN DIEGO , July 23, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM) and private Emirati health care company Pharma 1 Drug Store LLC have signed a License and Supply Agreement for the Middle East rights to... Read More

Evofem Acquires SOLOSEC, an FDA-Approved Single-Dose Treatment for Bacterial Vaginosis and Trichomoniasis MOUNTAIN VIEW, Calif. / Jul 17, 2024 / Business Wire / Aditxt, Inc. (“Aditxt”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announces this past Friday, July 12 th , Aditxt, its wholly owned subsidiary Adifem, Inc., and Evofem Biosciences, Inc.’s (“Evofem”)... Read More

Leading telemedicine company expands offering with hormone-free birth control as GLP-1 medication usage increases Hello Alpha partnership boosts awareness of and access to Phexxi for millions of women SAN DIEGO , June 27, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM) today announced a new market partnership with Hello Alpha , a telemedicine company with a medical team specifically... Read More

SAN DIEGO , May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate) , Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the first quarter of 2024. Highlights of and since the quarter include: Received $1 million from Aditxt, Inc. (Nasdaq: ADTX) in May 2024 in consideration for reinstating... Read More

MOUNTAIN VIEW, Calif. / May 03, 2024 / Business Wire / In the first and second paragraphs, shares of common stock should read: 1.6 million, (instead of 1.65 million). Second paragraph, second sentence, the conversion price of the Series C-1 Convertible Preferred Stock should read: $2.595 per share (instead of $2.47 per share). In the second paragraph, fourth sentence, the warrant exercise price should read: $2.47 (instead of... Read More

MOUNTAIN VIEW, Calif. / May 03, 2024 / Business Wire / Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into securities purchase agreements for the purchase and sale of an aggregate of 4,186 shares of the Company’s Series C-1 Convertible Preferred Stock, 4,186 shares of the Company’s D-1... Read More

Assets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical formulation MOUNTAIN VIEW, Calif. / Apr 02, 2024 / Business Wire / Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it... Read More

Third Consecutive Year of Phexxi Net Sales Growth Total Operating Expense Reduced 64% from 2022 Levels Sales and marketing expense as a percentage of net sales was 54% for the fourth quarter of 2023, the most favorable ratio since the Phexxi launch SAN DIEGO , March 27, 2024 /PRNewswire/ -- The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem... Read More

New weight loss drugs like Ozempic, Wegovy and Zepbound may make oral birth control pills less effective at certain points SAN DIEGO , March 7, 2024 /PRNewswire/ -- Use of GLP-1 receptor agonists, or GLP-1s, is skyrocketing in the United States , with more than nine million prescriptions for Ozempic, Wegovy, Mounjaro, and similar diabetes and obesity drugs written during the last three months of 2022 alone. 1 Zepbound weekly... Read More

Evofem Delivers Third Consecutive Year of Phexxi Net Sales Growth Total Operating Expense Reduced More Than 60% from 2022 Levels SAN DIEGO , Feb. 1, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced strong preliminary, unaudited results for fiscal 2023, including record net sales of Phexxi ® (lactic acid, citric acid, and potassium bitartrate) , its hormone-free contraceptive gel, and the Company's... Read More

The global EEG devices market was valued at $1.06 billion in 2022 and is anticipated to expand at a CAGR of 10.2% from 2023 to 2030 RICHMOND, Va. / Jan 30, 2024 / Business Wire / Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced the acquisition of a portfolio of EEG brain monitoring technologies and devices... Read More

This strategic acquisition positions Pearsanta for robust growth: expanding opportunities in women’s health, spanning endometriosis to ovarian cancer, and in men’s health starting with prostate cancer RICHMOND, Va. / Jan 08, 2024 / Business Wire / Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announces that the... Read More

RICHMOND, Va. / Jan 05, 2024 / Business Wire / Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,237,114 shares of common stock (or pre-funded warrants in lieu thereof)... Read More

RICHMOND, Va. / Jan 02, 2024 / Business Wire / Aditxt, Inc. (“Aditxt” or “the Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) Hearing Panel that it has regained compliance with minimum stockholders’ equity requirement in Nasdaq Listing Rule 5550(b)(1), subject to... Read More

RICHMOND, Va. / Dec 29, 2023 / Business Wire / Aditxt, Inc. , (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,237,114 shares of common stock (or pre-funded warrant in lieu thereof) at a purchase... Read More

Evofem posted $13.4 million in net sales of Phexxi for the first nine months of 2023; Aditxt looks to accelerate Evofem into the global non-hormonal birth control market valued at $27.7 billion in 2022 and is projected to grow to $52.2 billion by 2031 RICHMOND, Va. & SAN DIEGO / Dec 12, 2023 / Business Wire / Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and... Read More

Richmond, VA, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt” or the "Company"), an innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system will present at the 8th Annual Dawson James Conference on Thursday, October 12, 2023, at the Wyndam Grand Jupiter at Harbourside Place in Jupiter, Florida. Chief Executive... Read More

MOUNTAIN VIEW, Calif. / Oct 05, 2023 / Business Wire / Aditxt, Inc. , (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system, announced today that it has appointed Ernie Lee to serve as the Chief Executive Officer of the Company’s wholly-owned subsidiary Pearsanta, Inc. (“Pearsanta”).... Read More

JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8 th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand Hotel in Jupiter, FL. Dawson James’ flagship Small Cap Growth Conference brings together senior leadership from over 30 of the most... Read More

Aditxt Chairman, Co-Founder, and Chief Executive Officer Amro Albanna will deliver the company presentation on September 13 th at 4:30 p.m. EST. RICHMOND, Va. & MOUNTAIN VIEW, Calif. / Sep 08, 2023 / Business Wire / Aditxt, ® Inc , (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on developing and commercializing technologies that monitor and modulate the immune system, today announced that the... Read More

RICHMOND, Va. / Sep 06, 2023 / Business Wire / Aditxt, Inc. , (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 shares of common stock (or pre-funded warrants in lieu... Read More

RICHMOND, Va. / Aug 31, 2023 / Business Wire / Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 shares of common stock (or pre-funded warrant in lieu thereof) at a purchase... Read More

RICHMOND, Va. / Aug 18, 2023 / Business Wire / Aditxt®, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on innovation and activation of precision medicine therapeutics and technologies that monitor and modulate the immune system, is pleased to provide an important update regarding its innovation programs and strategic M&A initiatives. At Aditxt, our DNA is focused on bringing some of the... Read More

RICHMOND, Va. / Aug 17, 2023 / Business Wire / First paragraph, first sentence of release should read: Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced today that it will effect a 1-for-40 reverse split of its common stock (instead of Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt or the “Company”), a... Read More

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced today that it will effect a 1-for-40 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on August 18, 2023, the Company’s common stock will trade on a post-split basis under the same symbol ADTX.... Read More

The proposed acquisition is expected to act as a catalyst for strategic revenues while strengthening Pearsanta’s operational infrastructure and product offerings. The proposed acquisition is also intended to bring additional depth to Pearsanta’s roster of top-tier scientists and executives. Pearsanta’s commitment to precision medicine and supporting revenue growth would broaden with this acquisition, if completed, to... Read More

Adimune, Inc. is nearing completion of its pre-clinical package for the immunotherapy clinical study drug candidate ADI-100 Collaboration will initially target Stiff Person Syndrome, a rare, central nervous system disease frequently associated with other autoimmune diseases such as type-1 diabetes Clinical trial at Mayo Clinic is planned with enrollment of approximately 10-15 patients RICHMOND, Va. / May 05, 2023 / Business... Read More

RICHMOND, Va. / Apr 24, 2023 / Business Wire / Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the closing of its previously announced registered direct offering with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 1,585,350... Read More

RICHMOND, Va. / Apr 20, 2023 / Business Wire / Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 1,585,350 shares of common stock... Read More

This agreement is a significant step for Aditxt as it expands its portfolio to include innovative therapies for infectious diseases; Aditxt will partner with global logistics leader Agility to address a growing global market need for effective antivirals RICHMOND, Va. / Apr 20, 2023 / Business Wire / Aditxt,® Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies... Read More

RICHMOND, Va / Apr 17, 2023 / Business Wire / Aditxt,® Inc, (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to provide an important update regarding its three innovation programs and strategic M&A initiatives. PEARSANTA, INC.™ (IMMUNE MONITORING ) Aditxt’s Pearsanta Designated as the Backup Bidder in... Read More

RICHMOND, Va. / Mar 08, 2023 / Business Wire / Aditxt, Inc. , (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, is pleased to announce Maureen Connolly has joined Aditxt as Chief Content and Engagement Officer. Connolly is an award-winning content strategist and audience builder with 25+ years of... Read More

RICHMOND, Va. / Mar 03, 2023 / Business Wire / Aditxt, Inc. , (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces it has retained Riverside Management Group, LLC (“Riverside Management Group” or “RMG”), a merchant banking firm providing investment banking advisory services, to support the... Read More

RICHMOND, Va. / Feb 14, 2023 / Business Wire / Aditxt, Inc. , (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based wholly- owned subsidiary, Pearsanta, Inc. (“Pearsanta”), to accelerate the growth of Aditxt’s second program, AditxtScore™, through future strategic... Read More

Completion of GMP Drug Substances in January for Clinical Trials in H2, 2023 Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based subsidiary Adimune, Inc. (“Adimune™) and its plans towards submission of a Clinical Trial Application (“CTA”) for... Read More